News
CLVLF
7.50
NaN%
--
Clinuvel Files U.S. GAAP 20-F as It Targets Nasdaq ADR Uplisting
TipRanks · 12/18/2025 22:54
CLINUVEL Expands Singapore RD&I Centre for Advanced Peptide Therapies
TipRanks · 12/07/2025 22:47
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
Barchart · 12/07/2025 20:37
CLINUVEL Targets Mid-2026 for European Filing of NEURACTHEL® Instant
TipRanks · 12/02/2025 01:38
Clinuvel Pharmaceuticals Addresses Operational Challenges and Strategic Focus
TipRanks · 11/13/2025 22:24
Clinuvel Pharmaceuticals (CLVLF) was upgraded to a Buy Rating at Morgans
TipRanks · 11/11/2025 23:35
CLINUVEL Faces Potential Delays in Nasdaq Uplisting Amid U.S. Government Shutdown
TipRanks · 11/03/2025 00:48
Clinuvel Pharmaceuticals Emphasizes Strategic Cash Utilization for Sustained Growth
TipRanks · 10/17/2025 04:08
Clinuvel Pharmaceuticals: Strategic Execution and Growth at 2025 AGM
TipRanks · 10/17/2025 01:48
Health Canada Extends Review of CLINUVEL’s SCENESSE® for EPP
Barchart · 10/16/2025 21:54
Analysts Offer Insights on Healthcare Companies: Polynovo (OtherCALZF) and Clinuvel Pharmaceuticals (OtherCLVLF)
Barchart · 10/06/2025 23:12
Clinuvel Pharmaceuticals Issues Shares to Consultants
Barchart · 10/03/2025 19:42
Clinuvel Pharmaceuticals Announces Cessation of Securities
Barchart · 10/03/2025 19:42
CLINUVEL Pharmaceuticals Issues New Shares to Strengthen Market Position
Barchart · 10/03/2025 19:42
Clinuvel Pharmaceuticals Announces Quotation of New Securities
Barchart · 10/03/2025 19:26
More
Webull provides a variety of real-time CLVLF stock news. You can receive the latest news about Clinuvel Pharma through multiple platforms. This information may help you make smarter investment decisions.
About CLVLF
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.